Related references
Note: Only part of the references are listed.B-Cell Depletion With Rituximab in Patients With Primary Biliary Cirrhosis Refractory to Ursodeoxycholic Acid
Robert P. Myers et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Anticholestatic Effects of Bezafibrate in Patients with Primary Biliary Cirrhosis Treated with Ursodeoxycholic Acid
Akira Honda et al.
HEPATOLOGY (2013)
New Fibrate Use and Acute Renal Outcomes in Elderly Adults A Population-Based Study
Ying Y. Zhao et al.
ANNALS OF INTERNAL MEDICINE (2012)
Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy
Xiao Feng Han et al.
JOURNAL OF DIGESTIVE DISEASES (2012)
Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis
Teru Kumagi et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
TNFSF9 expression in primary biliary cirrhosis and its clinical significance
Rong Xia et al.
CYTOKINE (2010)
Fenofibrate in Primary Biliary Cirrhosis: A Pilot Study
E. N. Liberopoulos et al.
OPEN CARDIOVASCULAR MEDICINE JOURNAL (2010)
Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid
Edith M. M. Kuiper et al.
GASTROENTEROLOGY (2009)
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Christophe Corpechot et al.
HEPATOLOGY (2008)
The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study
Shinji Iwasaki et al.
HEPATOLOGY RESEARCH (2008)
Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients
Pieter C. J. ter Borg et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: A meta-analysis of randomized controlled trials
Jian Shi et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid
A Parés et al.
GASTROENTEROLOGY (2006)
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis
B Combes et al.
HEPATOLOGY (2005)
Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis
J Itakura et al.
HEPATOLOGY RESEARCH (2004)
Peroxisome proliferator-activated receptor α (PPARα)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice
T Kok et al.
BIOCHEMICAL JOURNAL (2003)
Primary biliary cirrhosis: Incidence and predictive factors of cirrhosis development in ursodiol-treated patients
C Corpechot et al.
GASTROENTEROLOGY (2002)
Serum interferon-gamma-inducing factor/IL-18 levels in primary biliary cirrhosis
T Yamano et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2000)
Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid
P Angulo et al.
HEPATOLOGY (2000)
The PPARs: From orphan receptors to drug discovery
TM Willson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
